Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial

被引:209
作者
Audet, MC
Moreau, M
Koltun, WD
Waldbaum, AS
Shangold, G
Fisher, AC
Creasy, GW
机构
[1] RW Johnson Pharmaceut Res Inst, Dept Clin Res, Raritan, NJ 08869 USA
[2] Ctr Med Halles de St Foy, Ste Foy, PQ, Canada
[3] Ctr Hosp Univ Montreal, Dept Obstet Gynecol, Montreal, PQ, Canada
[4] Med Ctr Womens Clin Res, San Diego, CA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2001年 / 285卷 / 18期
关键词
D O I
10.1001/jama.285.18.2347
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Oral contraceptive (OC) pills are effective, but poor compliance increases rates of pregnancy during treatment. Objective To compare the contraceptive efficacy, cycle control, compliance, and safety of a transdermal contraceptive patch and an OC, Design Randomized, open-label, parallel-group trial conducted October 1997 to June 1999. Setting Forty-five clinics in the United States and Canada. Participants A total of 1417 healthy adult women of child-bearing potential. Interventions Participants were randomly assigned to receive a transdermal contraceptive patch (n=812) vs an OC (n=605) for 6 or 13 cycles. Patch treatment consisted of application of 3 consecutive 7-day patches followed by 1 patch-free week. Main Outcome Measures Overall and method-failure Pearl Indexes (number of pregnancies/100 person-years of use) and life-table estimates of the probability of pregnancy were calculated. Cycle control, compliance, patch adhesion, and adverse events were also assessed. Results Overall and method-failure Pearl Indexes were numerically lower with the patch (1.24 and 0.99, respectively) vs the OC (2.18 and 1.25, respectively); this difference was not statistically significant (P=.57 and .80, respectively), The incidence of breakthrough bleeding and/or spotting was significantly higher only in the first 2 cycles in the patch group, but the incidence of breakthrough bleeding alone was comparable between treatments in all cycles. The mean proportion of participants' cycles with perfect compliance was 88.2% (811 total participants, 5141 total cycles) with the patch and 77.7% (605 total participants, 4134 total cycles) with the OC (P <.001). Only 1.8% (300/16673) of patches completely detached. Both treatments were similarly well tolerated; however, application site reactions, breast discomfort, and dysmenorrhea were significantly more common in the patch group. Conclusion The contraceptive patch is comparable to a combination OC in contraceptive efficacy and cycle control. Compliance was better with the weekly contraceptive patch than with the OC.
引用
收藏
页码:2347 / 2354
页数:8
相关论文
共 23 条
[1]  
Abrams L, 2000, FASEB J, V14, pA1479
[2]  
Abrams LS, 2000, CLIN PHARMACOL THER, V67, P105
[3]  
Abrams LS, 2000, CLIN PHARMACOL THER, V67, P106
[4]  
Bishop Y.M.M., 1975, DISCRETE MULTIVARIAT, P486
[5]  
*COMM PROPR MED PR, 2000, NOT GUID CLIN INV ST, P3
[6]  
CREASY G, 2000, FERTIL STERIL, V74, pS185
[7]  
CREASY G, 1995, OBSTET GYNECOL S, V95, pS60
[8]  
CROMER BA, 1994, PEDIATRICS, V94, P687
[9]   Contraceptive failure rates: New estimates from the 1995 National Survey of Family Growth [J].
Fu, HS ;
Darroch, JE ;
Haas, T ;
Ranjit, N .
FAMILY PLANNING PERSPECTIVES, 1999, 31 (02) :56-63
[10]  
Hatcher RA, 1998, CONTRACEPTIVE TECHNO, P405